levonadifloxacin

broad-spectrum anti-MRSA benzoquinolizine quinolone agent; alalevonadifloxacin is prodrug of levonadifloxacin

Also Known As:

(12S)-8-(4-((2S)-2-aminopropanoyl)oxypiperidin-1-yl)-7-fluoro-12-methyl-4-oxo-1-azatricyclo(7.3.1.05,13)trideca-2,5,7,9(13)-tetraene-3-carboxylic acid; (S)-(-)-nadifloxacin; EMROK; EMROK O; L-Alanine, 1-((5S)-2-carboxy-9-fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizin-8-yl)-4-piperidinyl ester; WCK 2349; alalevonadifloxacin

Networked: 23 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        levonadifloxacin: 23
    - Quinolizines: 1
      - levonadifloxacin: 23

Experts

1.	Patel, Mahesh: 5 articles (01/2022 - 01/2019)
2.	Yeole, Ravindra: 5 articles (01/2022 - 01/2018)
3.	Patel, Anasuya: 3 articles (01/2022 - 01/2018)
4.	Bhagwat, Sachin: 3 articles (12/2021 - 01/2020)
5.	Jain, Rishi: 3 articles (12/2020 - 01/2019)
6.	Bhagwat, Sachin S: 3 articles (01/2019 - 12/2004)
7.	Debnath, Khokan: 2 articles (04/2022 - 01/2022)
8.	Gupta, Sangita: 2 articles (01/2022 - 01/2020)
9.	Kansagara, Atul: 2 articles (01/2022 - 01/2019)
10.	Nandanwar, Manohar: 2 articles (01/2022 - 01/2019)

Related Diseases

1.	Bacterial Infections (Bacterial Infection) 01/01/2022 - "Prescription-Event Monitoring Study on Safety and Efficacy of Levonadifloxacin (Oral and I.V.) in Management of Bacterial Infections: Findings of Real-World Observational Study." 01/01/2022 - "Overall, 96.3% and 97.3% of investigators rated the efficacy and safety of levonadifloxacin as "good to excellent." An excellent safety and efficacy profile of levonadifloxacin was observed in this study making it a suitable treatment option for management of various bacterial infections, including those caused by resistant Gram-positive pathogens such as MRSA and quinolone-resistant S. " 01/01/2018 - "The observed plasma, ELF, and AM concentrations of levonadifloxacin support further studies of alalevonadifloxacin for treatment of lower respiratory tract bacterial infections caused by susceptible pathogens. "
2.	Infections 04/01/2022 - "Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study." 01/01/2019 - "The present study identified area under the concentration-time curve for the free, unbound fraction of a drug divided by the MIC (fAUC/MIC) as an efficacy determinant for levonadifloxacin in a neutropenic murine lung infection model. " 11/01/2018 - "pneumoniae, and 2 μg/ml for Ureaplasma spp. Levonadifloxacin merits further study for treating infections caused by these organisms." 01/01/2022 - "Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin." 06/01/2021 - "Alalevonadifloxacin (ALA) is a novel antibacterial drug, recently launched in India to treat infections caused by Gram-positive bacteria. "
3.	Phototoxic Dermatitis (Phototoxicity) 01/01/2022 - "Owing to FQ-associated safety concerns, extensive preclinical safety pharmacology (central nervous system and cardiac safety) and toxicology studies (subacute repeat-dose toxicity, genotoxicity, phototoxicity and chondrotoxicity) of levonadifloxacin were performed at relatively high doses. " 01/01/2022 - "WCK 771 and WCK 2349 were found to be nongenotoxic; however, they showed weak phototoxicity that was comparable with levofloxacin. "
4.	Diabetic Foot 08/01/2020 - "Both oral and IV levonadifloxacin have recently been granted approval in India for the treatment of ABSSSI including diabetic foot infections and concurrent bacteraemia in adults (18 years of age or older). " 08/01/2020 - "Levonadifloxacin showed evidence of favourable clinical and microbiological efficacy in subjects with concurrent bacteraemia as well as in subjects with diabetes including diabetic foot infections caused by Gram-positive pathogens including MRSA. " 07/01/2020 - "Levonadifloxacin and its oral prodrug, alalevonadifloxacin, have been recently approved in India for the treatment of acute bacterial skin and skin structure infections, including concurrent bacteraemia and diabetic foot infections. " 01/01/2020 - "IV levonadifloxacin and its oral prodrug alalevonadifloxacin have recently been approved in India for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) including diabetic foot infections. " 01/01/2022 - "Patients were prescribed levonadifloxacin for skin and soft-tissue infections, diabetic foot infections, septicemia, catheter-related bloodstream infections, bone and joint infections, febrile neutropenia, and respiratory infections including COVID-19 pneumonia. "
5.	Staphylococcal Infections 12/01/2019 - "Therefore, levonadifloxacin has the potential to be a therapeutic option for the management of intracellular methicillin- and quinolone-resistant staphylococcal infections." 12/01/2004 - "WCK 771, the arginine salt of S-(-)-nadifloxacin, was evaluated in animal models of staphylococcal infection and in vitro. "

Related Drugs and Biologics

1.	Quinolones
2.	levonadifloxacin
3.	Linezolid (Zyvox)
4.	Prodrugs
5.	Fluoroquinolones
6.	Salts
7.	Arginine (L-Arginine)
8.	WCK 771
9.	Anti-Bacterial Agents (Antibiotics)
10.	Levofloxacin (Levaquin)

Related Therapies and Procedures

1.	Catheters
2.	Therapeutics
3.	Oral Administration